Bliss GVS Pharma Latest Share Price (BLISSGVS)
TODAY IN ONE LINE
With a market cap of ₹6,080.2 Cr., it trades at a P/E of 44.69. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Bliss GVS Pharma flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 124.7% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 13.0% and Profit up 108.0%
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●High Leverage RiskDebt-to-Equity is elevated at 1.77x
Latest Bliss GVS Pharma News
What changed recently?
Recent events, corporate actions, and announcements.
Bliss GVS Pharma Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Bliss GVS Pharma Limited, framed against the sector median so the premium or discount is obvious at a glance.
Bliss GVS Pharma Limited trades at a P/E of 44.69× and P/B of 5.10×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Bliss GVS Pharma Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Bliss GVS Pharma Limited — derived from the latest tape, not yesterday's close.
Bliss GVS Pharma Limited last traded at ₹527.1 with an intraday range of ₹523.55–₹532.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹527.10| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 550.58 | +23.48 | +4.46% |
| R3 | 541.33 | +14.23 | +2.70% |
| R2 | 537.07 | +9.97 | +1.89% |
| R1 | 532.08 | +4.98 | +0.95% |
| PIVOT | 527.82 | 0.72 | 0.14% |
| CURRENT | 527.10 | — | — |
| S1 | 522.83 | -4.27 | -0.81% |
| S2 | 518.57 | -8.53 | -1.62% |
| S3 | 513.58 | -13.52 | -2.56% |
| S4 | 504.33 | -22.77 | -4.32% |
BLISSGVS is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹–₹
Trading Inside opening range
Bliss GVS Pharma Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Bliss GVS Pharma Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Bliss GVS Pharma Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,080.2 Cr. and reported EPS of ₹11.99.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 810 | 927 ▲ 14.5% |
| Sales Growth YoY %Derived | 5.13% | 14.50% |
| Other Income | 36 | 74 ▲ 101.5% |
| Total Income | 846 | 1,001 ▲ 18.2% |
| 414 | 425 ▲ 2.7% | |
| Gross ProfitDerived | 396 | 502 ▲ 26.8% |
| Gross Margin %Derived | 48.91% | 54.15% |
| 269 | 338 ▲ 25.5% | |
| EBITDA (Operating Profit)Derived | 127 | 164 ▲ 29.5% |
| OPM %Derived | 15.65% | 17.69% |
| 38 | 43 ▲ 14.6% | |
| Profit Before Tax (PBT) | 126 | 190 ▲ 50.9% |
| 35 | 55 ▲ 55.0% | |
| Effective Tax %Derived | 28.16% | 28.94% |
| Total Profit for Period | 90 | 135 ▲ 49.3% |
| Less: Non-controlling Interests | 6 | 6 ▼ 6.0% |
| Net Profit (Owner's PAT)Derived | 84 | 129 ▲ 53.2% |
| Net Profit Margin %Derived | 10.41% | 13.93% |
| PAT Growth YoY %Derived | 11.72% | 53.18% |
| Earnings Per Share (EPS ₹) | 8.00 | 12.21 ▲ 52.6% |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.4% |
| Other Comprehensive Income (Net of Tax) | -2 | 2 ▲ 186.6% |
| Total Expenses (incl. D&A & Interest) | 721 | 811 ▲ 12.6% |
| Material Cost % of RevenueDerived | 46.00% | 41.66% |
| Employee Cost % of RevenueDerived | 13.84% | 14.72% |
| Other Cost % of RevenueDerived | 19.43% | 21.74% |
| Interest Coverage (x)Derived | 11.98x | 10.87x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 258 | 898 ▲ 247.6% | 689 ▼ 23.3% | 577 ▼ 16.3% | 747 ▲ 29.5% | 752 ▲ 0.6% | 770 ▲ 2.5% | 810 ▲ 5.1% | 927 ▲ 14.5% | |
| Sales Growth YoY %Derived | — | 247.65% | -23.26% | -16.26% | 29.50% | 0.55% | 2.48% | 5.13% | 14.50% | |
| Other Income | -7 | 38 ▲ 649.9% | 37 ▼ 1.4% | 20 ▼ 45.5% | 31 ▲ 55.7% | 18 ▼ 43.5% | 29 ▲ 61.6% | 36 ▲ 27.0% | 74 ▲ 101.5% | |
| Total Income | 252 | 936 ▲ 272.1% | 726 ▼ 22.4% | 597 ▼ 17.8% | 779 ▲ 30.4% | 769 ▼ 1.2% | 799 ▲ 3.8% | 846 ▲ 5.9% | 1,001 ▲ 18.2% | |
95 | 612 ▲ 547.5% | 440 ▼ 28.1% | 329 ▼ 25.2% | 391 ▲ 18.9% | 401 ▲ 2.6% | 382 ▼ 4.8% | 414 ▲ 8.3% | 425 ▲ 2.7% | ||
| Gross ProfitDerived | 164 | 286 ▲ 74.6% | 249 ▼ 12.8% | 248 ▼ 0.4% | 356 ▲ 43.6% | 350 ▼ 1.7% | 388 ▲ 10.8% | 396 ▲ 2.0% | 502 ▲ 26.8% | |
| Gross Margin %Derived | 63.41% | 31.84% | 36.17% | 43.02% | 47.69% | 46.60% | 50.39% | 48.91% | 54.15% | |
88 | 128 ▲ 46.3% | 126 ▼ 1.7% | 142 ▲ 12.3% | 238 ▲ 68.1% | 233 ▼ 2.2% | 238 ▲ 2.0% | 269 ▲ 13.4% | 338 ▲ 25.5% | ||
| EBITDA (Operating Profit)Derived | 76 | 158 ▲ 107.1% | 123 ▼ 21.8% | 107 ▼ 13.5% | 118 ▲ 11.0% | 117 ▼ 0.9% | 151 ▲ 28.4% | 127 ▼ 15.9% | 164 ▲ 29.5% | |
| OPM %Derived | 29.45% | 17.55% | 17.88% | 18.48% | 15.83% | 15.61% | 19.56% | 15.65% | 17.69% | |
9 | 13 ▲ 50.7% | 5 ▼ 65.4% | 23 ▲ 392.6% | -52 ▼ 326.5% | 29 ▲ 156.4% | 4 ▼ 85.9% | 38 ▲ 816.5% | 43 ▲ 14.6% | ||
| Profit Before Tax (PBT) | 60 | 182 ▲ 201.2% | 129 ▼ 29.1% | 104 ▼ 19.3% | 54 ▼ 48.0% | 106 ▲ 95.8% | 117 ▲ 10.2% | 126 ▲ 7.5% | 190 ▲ 50.9% | |
18 | 55 ▲ 210.5% | 34 ▼ 39.0% | 30 ▼ 10.6% | 31 ▲ 2.9% | 29 ▼ 5.5% | 35 ▲ 20.3% | 35 ▲ 0.3% | 55 ▲ 55.0% | ||
| Effective Tax %Derived | 29.47% | 30.37% | 26.14% | 28.96% | 57.30% | 27.66% | 30.20% | 28.16% | 28.94% | |
| Total Profit for Period | 43 | 127 ▲ 197.3% | 95 ▼ 24.8% | 74 ▼ 22.3% | 23 ▼ 68.7% | 77 ▲ 231.8% | 82 ▲ 6.3% | 90 ▲ 10.6% | 135 ▲ 49.3% | |
| Less: Non-controlling Interests | 9 | 3 ▼ 69.0% | -2 ▼ 168.4% | 6 ▲ 390.3% | 8 ▲ 38.4% | 6 ▼ 27.3% | 6 ▲ 4.2% | 6 ▼ 2.7% | 6 ▼ 6.0% | |
| Net Profit (Owner's PAT)Derived | 33 | 124 ▲ 273.5% | 97 ▼ 21.4% | 68 ▼ 30.0% | 15 ▼ 77.9% | 71 ▲ 371.1% | 75 ▲ 6.5% | 84 ▲ 11.7% | 129 ▲ 53.2% | |
| Net Profit Margin %Derived | 12.82% | 13.77% | 14.11% | 11.80% | 2.01% | 9.43% | 9.80% | 10.41% | 13.93% | |
| PAT Growth YoY %Derived | — | 273.52% | -21.38% | -29.95% | -77.92% | 371.13% | 6.49% | 11.72% | 53.18% | |
| Earnings Per Share (EPS ₹) | 3.21 | 12.96 ▲ 303.7% | 9.43 ▼ 27.2% | 6.64 ▼ 29.6% | 1.45 ▼ 78.2% | 6.80 ▲ 369.0% | 7.21 ▲ 6.0% | 8.00 ▲ 11.0% | 12.21 ▲ 52.6% | |
| Diluted Shares Outstanding (Cr) | 10 | 10 ▲ 0.0% | 10 ▲ 0.0% | 10 ▲ 0.0% | 10 ▲ 0.5% | 10 ▲ 0.5% | 10 ▲ 0.5% | 11 ▲ 0.6% | 11 ▲ 0.4% | |
| Other Comprehensive Income (Net of Tax) | -13 | -2 ▲ 84.7% | 4 ▲ 281.9% | -1 ▼ 114.0% | -7 ▼ 1344.5% | -6 ▲ 13.9% | 5 ▲ 171.3% | -2 ▼ 151.6% | 2 ▲ 186.6% | |
| Total Expenses (incl. D&A & Interest) | 191 | 754 ▲ 294.5% | 597 ▼ 20.8% | 493 ▼ 17.4% | 725 ▲ 46.9% | 663 ▼ 8.5% | 682 ▲ 2.8% | 721 ▲ 5.6% | 811 ▲ 12.6% | |
| Material Cost % of RevenueDerived | 32.01% | 24.20% | 37.23% | 45.01% | 51.54% | 43.91% | 44.03% | 46.00% | 41.66% | |
| Employee Cost % of RevenueDerived | 7.73% | 4.71% | 7.79% | 11.80% | 10.19% | 11.46% | 12.41% | 13.84% | 14.72% | |
| Other Cost % of RevenueDerived | 26.22% | 9.58% | 10.51% | 12.74% | 21.67% | 19.53% | 18.43% | 19.43% | 21.74% | |
| Interest Coverage (x)Derived | 9.74x | 33.68x | 20.45x | 16.22x | 21.30x | 9.52x | 17.97x | 11.98x | 10.87x |
Bliss GVS Pharma segment analysis : revenue and profit mix.
Disclosed business segments at Bliss GVS Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Bliss GVS Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Bliss GVS Pharma Limited.
Our AI distills the core fundamental drivers supporting Bliss GVS Pharma Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Bliss GVS Pharma Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 128.9% YoY, demonstrating explosive earnings momentum.
TTM EPS grew 124.7% YoY, sustaining strong profit acceleration despite market headwinds.
Operating margin 14.08% reflects solid operational efficiency in competitive pharma sector.
Net profit margin 13.9% indicates strong pricing power and cost management capabilities.
Debt-to-equity ratio 0.0177 shows exceptionally low leverage and robust financial flexibility.
Key Risks.
FII holdings declined from 17.17% to 12.65%, signaling reduced foreign investor confidence.
Dividend yield 0.19% offers minimal income return for equity shareholders.
ROE 8.36% lags peer benchmarks, indicating suboptimal capital efficiency.
ROCE 11.70% below industry leaders, suggesting weaker returns on invested capital.
Net debt negative at ₹1,933 Cr indicates persistent cash burn despite operating profits.
Flip Conditions.
Valuation risk. a P/E above 58 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 2.27. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 0.10%.
Bliss GVS Pharma Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Bliss GVS Pharma Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Bliss GVS Pharma Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Bliss GVS Pharma Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Bliss GVS Pharma Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Bliss GVS Pharma Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Bliss GVS Pharma Limited stood at 53.7% of traded volume, against a 20-day average of 44.4%.
Bliss GVS Pharma announcements: results, concalls, ratings, M&A.
Filings Bliss GVS Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Bliss GVS Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 107 documents below.
Copy of Newspaper Publication
Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the Advertisement of the Postal Ballot Notice.
Shareholders meeting
Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
Copy of Newspaper Publication
Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the extract of the statement of un-audited…
General Updates
Bliss GVS Pharma Limited has informed the Exchange about General Updates regarding grant of options under Bliss GVS Pharma Limited - Employee Stock…
Outcome of Board Meeting
Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026 along with the Limited Review Report…
Investor decks & rating reports.
Bliss GVS Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Bliss GVS Pharma has declared, sequenced by announce and record date.
Bliss GVS Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Bliss GVS Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Bliss GVS Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Bliss GVS Pharma insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mr. Gagan Harsh Sharma | Insider | 10 Jun 2025 | buy | +2.0 K | ₹2.69 L | ₹136.73 |
| Mr. Gagan Harsh Sharma | Insider | 09 Jun 2025 | buy | +46.7 K | ₹63.78 L | ₹136.70 |
| Mr. Gagan Harsh Sharma | Insider | 22 May 2025 | buy | +4.7 K | ₹5.72 L | ₹121.48 |
| Mr. Gagan Harsh Sharma | Insider | 21 May 2025 | buy | +37.3 K | ₹45.16 L | ₹121.20 |
| Mr. Gagan Harsh Sharma | Insider | 20 May 2025 | buy | +41.6 K | ₹50.54 L | ₹121.47 |
| Mrs. Vibha Gagan Sharma | Insider | 21 Mar 2025 | buy | +25.0 K | ₹30.66 L | ₹122.63 |
| Mrs. Vibha Gagan Sharma | Insider | 20 Mar 2025 | buy | +75.0 K | ₹90.47 L | ₹120.63 |
| Mr. Narsimha Shibroor Kamath | Insider | 19 Feb 2025 | buy | +23.0 K | ₹30.73 L | ₹133.59 |
| Mr. Narsimha Shibroor Kamath | Insider | 18 Feb 2025 | buy | +77.0 K | ₹98.19 L | ₹127.52 |
About Bliss GVS Pharma Limited: business, sector, key facts.
What Bliss GVS Pharma Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Bliss GVS Pharma Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BLISSGVS, BSE: 506197.
Bliss GVS Pharma Limited is a pharmaceutical company headquartered in Mumbai, India, established in 1984. Their core business centers around the development, manufacture, and marketing of a diverse range of pharmaceutical formulations both domestically within India and internationally through exports.
The company's product portfolio is extensive and encompasses a wide spectrum of dosage forms. This includes capsules, tablets (including effervescent), injections, suspensions, liquids, creams, ointments, gels, eye and ear drops, suppositories, pessaries, transdermal patches, and other topical preparations like lotions, balms, and sprays. They also produce various other healthcare products such as soaps, shampoos, nasal inhalers, and personal care items.
Bliss GVS's therapeutic areas covered are equally broad, reflecting their commitment to providing a comprehensive range of medications. Their offerings include products addressing pain relief (analgesics), digestive issues (antacids, anti-diarrheals, anti-emetics), infections (antibacterials, antifungals, anti-infectives), respiratory ailments (cough syrups, nasal decongestants), cardiovascular conditions, and many other therapeutic categories. This spans anti-diabetic, anti-inflammatory, anti-malarial, anti-helminthic and numerous other therapeutic areas, along with products for specific conditions such as erectile dysfunction, laryngitis, and pharyngitis. Furthermore, they offer health supplements, vitamins, and other over-the-counter (OTC) products.
In addition to their core pharmaceutical offerings, Bliss GVS expands into related health and personal care areas. They provide products like health and nutritional supplements, vitamin supplements, amino acid preparations, iron tonics, insect repellants, moisturizers, and vaginal hygiene products. This diversification demonstrates a strategy to cater to a wider consumer base beyond prescription medications.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Bliss GVS Pharma Limited (BLISSGVS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Bliss GVS Pharma Limited (BLISSGVS)?
The current share price of Bliss GVS Pharma Limited (BLISSGVS) is ₹527.10. Today, the stock has gained by ₹3.55 (0.68%), trading in a range of ₹523.55 to ₹532.80. The stock opened at ₹523.55 with a trading volume of 3,93,278 shares.
02Is Bliss GVS Pharma Limited stock a good investment for long-term?
Bliss GVS Pharma Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,080.2 Cr., P/E ratio of 44.69, ROE of 0%, and ROCE of 11.7%. The dividend yield stands at 0.19%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Bliss GVS Pharma Limited stock?
The 52-week high price of Bliss GVS Pharma Limited (BLISSGVS) is ₹553.00, while the 52-week low is ₹118.00. Currently trading at ₹527.10, the stock is 346.69% above its 52-week low and 4.68% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Bliss GVS Pharma Limited stock at the current price?
Whether to buy Bliss GVS Pharma Limited stock at ₹527.10 depends on multiple factors. The stock is currently trading with a P/E ratio of 44.69 and P/B ratio of 5.1. Today's performance shows a gain of 0.68%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Bliss GVS Pharma Limited and when is the next dividend?
Bliss GVS Pharma Limited offers a dividend yield of 0.19%, which means for every ₹100 invested at the current price of ₹527.10, you can expect to receive approximately ₹0.19 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Bliss GVS Pharma Limited?
Bliss GVS Pharma Limited's key financial metrics include: P/E Ratio: 44.69, P/B Ratio: 5.1, ROE: 0%, ROCE: 11.7%, Dividend Yield: 0.19%, EPS: ₹11.99, Book Value: ₹107.21, and Debt-to-Equity: 1.77. The company's market cap stands at ₹6,080.2 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Bliss GVS Pharma Limited stock performing today in the market?
Bliss GVS Pharma Limited stock opened at ₹523.55 and is currently trading at ₹527.10, showing a gain of ₹3.55 (0.68%). The intraday high is ₹532.80 and low is ₹523.55. The trading volume stands at 3,93,278 shares, indicating moderate market participation today.
08What is the P/E ratio of Bliss GVS Pharma Limited and what does it indicate?
Bliss GVS Pharma Limited has a Price-to-Earnings (P/E) ratio of 44.69, which means investors are willing to pay 44.69 for every ₹1 of earnings. With an EPS of ₹11.99, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Bliss GVS Pharma Limited (BLISSGVS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.